Enfermedad pulmonar intersticial fibrosante progresiva (EPI-FP)
Effect of nintedanib on FVC decline in patients with progressive fibrosing ILDs: data from the INBUILD trial
Cottin V et al.
Effects of nintedanib on dyspnea, cough and quality of life in patients with progressive fibrosing interstitial lung diseases: findings from the INBUILD trial
Swigris JJ et al.
Does HRCT pattern influence the effect of nintedanib in patients with progressive fibrosing interstitial lung diseases?
Brown KK et al.
Effect of nintedanib in patients with progressive fibrosing interstitial lung diseases: subgroup analyses from the INBUILD trial
Kolb M et al.
Safety and tolerability of nintedanib in patients with fibrosing ILDs: a comparison of the INBUILD and INPULSIS trials
Martinez FJ et al.
Improving our understanding of progressive fibrosing interstitial lung diseases (ILDs): design of the ILD-PRO Registry
Palmer SM et al.
Study design of a Phase III, randomized, placebo-controlled trial of nintedanib in children and adolescents with clinically significant fibrosing interstitial lung disease (ILD)
Young L et al.
Identifying key considerations for early identification of interstitial lung disease: a Delphi consensus study
Hunninghake M et al.
